PBYI Overview
Upcoming Projects (PBYI)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PBYI)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (PBYI)
-
Discussing Puma Bio’s neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer
Ticker: PBYI
Execute By: Jan 31, 2023
Upcoming & Overdue Catalysts (PBYI)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (PBYI)
-
Final 5-year DFS data from ExteNET expected in the second half of 2017
Ticker: PBYI
Occurred on: Sep 08, 2017 -
Phase 3 data of Neratinib in Third-line HER2-positive metastatic breast cancer due 1st half of 2017
Ticker: PBYI
Occurred on: Sep 08, 2017 -
Regulatory decision in the EU on neratinib in extended adjuvant HER2 positive early stage breast cancer expected in Q3 2017
Ticker: PBYI
Occurred on: Jul 17, 2017 -
FDA's Oncologic Drugs Advisory Committee to Review Puma's (PBYI) New Drug Application for Neratinib in HER-2 Positive Breast Cancer
Ticker: PBYI
Occurred on: Apr 17, 2017 -
Phase II CONTROL trial (loperamide + budesonide) additional data expected in Q2 2017
Ticker: PBYI
Occurred on: Apr 04, 2017 -
Interim Phase Ib/II data fron neratinib plus Kadcyla (T-DM1) in HER2-positive metastatic breast cancer trial expected Q2 2017
Ticker: PBYI
Occurred on: Apr 02, 2017 -
Phase II data from SUMMIT basket trial of neratinib in patients with HER2 mutations expected Q2 2017
Ticker: PBYI
Occurred on: Apr 02, 2017 -
Phase 2 data of Neratinib SUMMIT in HER2 non-amplified breast cancer that has a HER2 mutation due 4Q 2016
Ticker: PBYI
Occurred on: Dec 07, 2016 -
NDA filling of PB272 for the extended adjuvant HER2-positive early stage breast cancer due 1Q 2016
Ticker: PBYI
Occurred on: Jul 27, 2016 -
NDA Filing for neratinib set for mid-2016
Ticker: PBYI
Occurred on: Jul 21, 2016 -
Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine
Ticker: PBYI
Occurred on: Jul 07, 2016 -
Puma Biotechnology Announces Results from ExteNET Phase III Clinical Trial of Neratinib
Ticker: PBYI
Occurred on: Feb 11, 2016 -
Puma to host an investor call to discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea
Ticker: PBYI
Occurred on: Dec 21, 2015
Strategic Initiatives (PBYI)
-
Don’t see a strategic initiative related to the company you care about? Create your own!